Short answer
OmniAb, Inc. (OABI) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 and six-month financial results for periods ended June 30, 2026, announced August 6, 2026.
OmniAb, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 and six-month financial results for periods ended June 30, 2026, announced August 6, 2026
- Detailed results and management commentary contained in Exhibit 99.1
- Press release furnished under Form 8-K Item 2.02, not filed under Exchange Act Section 18orlutik
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $13.4M vs $3.9M, driven primarily by milestone revenue; first-half revenue reached $27.8M
- Net loss narrowed to $5.9M, or $0.05 per share, from $15.9M, or $0.15, year over year
- 2026 revenue guidance raised to $32M-$36M from $28M-$33M, signaling stronger partner and milestone momentum
- Year-end cash guidance raised to $37M-$41M; June 30 cash, equivalents and short-term investments totaled $52.0M
- Portfolio momentum strengthened with 34 OmniAb-derived programs in clinical development or commercialization across 110 partners and 425 programs
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other OmniAb, Inc. 8-K filings
Get the next OABI 8-K as it lands
Follow OABI for push alerts, or ask the research agent what this filing means.